1. Home
  2. VINC vs REVB Comparison

VINC vs REVB Comparison

Compare VINC & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VINC
  • REVB
  • Stock Information
  • Founded
  • VINC 2019
  • REVB 2020
  • Country
  • VINC United States
  • REVB United States
  • Employees
  • VINC N/A
  • REVB N/A
  • Industry
  • VINC Biotechnology: Pharmaceutical Preparations
  • REVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • VINC Health Care
  • REVB Health Care
  • Exchange
  • VINC Nasdaq
  • REVB Nasdaq
  • Market Cap
  • VINC 6.2M
  • REVB 5.4M
  • IPO Year
  • VINC N/A
  • REVB N/A
  • Fundamental
  • Price
  • VINC $0.15
  • REVB $0.40
  • Analyst Decision
  • VINC Buy
  • REVB
  • Analyst Count
  • VINC 2
  • REVB 0
  • Target Price
  • VINC $2.00
  • REVB N/A
  • AVG Volume (30 Days)
  • VINC 21.3M
  • REVB 6.8M
  • Earning Date
  • VINC 11-12-2024
  • REVB 11-08-2024
  • Dividend Yield
  • VINC N/A
  • REVB N/A
  • EPS Growth
  • VINC N/A
  • REVB N/A
  • EPS
  • VINC N/A
  • REVB N/A
  • Revenue
  • VINC N/A
  • REVB N/A
  • Revenue This Year
  • VINC N/A
  • REVB N/A
  • Revenue Next Year
  • VINC N/A
  • REVB N/A
  • P/E Ratio
  • VINC N/A
  • REVB N/A
  • Revenue Growth
  • VINC N/A
  • REVB N/A
  • 52 Week Low
  • VINC $0.14
  • REVB $0.28
  • 52 Week High
  • VINC $9.37
  • REVB $25.26
  • Technical
  • Relative Strength Index (RSI)
  • VINC 37.12
  • REVB 39.87
  • Support Level
  • VINC $0.14
  • REVB $0.39
  • Resistance Level
  • VINC $0.52
  • REVB $0.53
  • Average True Range (ATR)
  • VINC 0.04
  • REVB 0.13
  • MACD
  • VINC -0.00
  • REVB 0.00
  • Stochastic Oscillator
  • VINC 3.25
  • REVB 7.54

About VINC Vincerx Pharma Inc.

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: